Our Products and Services
DemeRx is currently evaluating patient data which demonstrate that a single dose of ibogaine is sufficient to detoxify opioid-dependent persons and diminish drug cravings for extended time periods.
DemeRx is evaluating the safety and pharmacokinetics of ibogaine in normal healthy volunteers and in patients with opioid abuse problems.
DemeRx-IB is advancing ibogaine in clinical trials to demonstrate its use as an effective, non-opioid addiction treatment for withdrawal management and relapse prevention
Drug abuse “hijacks” the brain’s reward centers
ibogaine “reset” turns on plasticity to heal the addicted brain
Rapid management of opioid withdrawal symptoms
Lasting effect on behavior to prevent relapse to opioids
Bridging the research to clinical practice gap
We plan to advance ibogaine for opioid withdrawal management and relapse prevention in medically supervised inpatient settings. noribogaine will be developed as a low-dose therapy for patients in early recovery among other indications.
Our drug products may offer better outcomes for patients suffering from alcohol and opioid use disorders, including better treatment retention, decreases in illegal opioid use, and a decrease in risky behaviors related to HIV and hepatitis C.